BIO vs CVS: fair value comparison
Bio-Rad Laboratories, Inc. and CVS Health Corporation · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CVS currently sits closer to the top of our discount ranking. BIO carries the stronger quality grade.
| BIO | CVS | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $330.01 | $93.06 |
| 12-month range | $256.55–$334.71 | $72.49–$105.37 |
| Sector rank | #89 of 113 Healthcare | #88 of 113 Healthcare |
| Quality grade | B | F |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Overbought | Oversold |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: BIO fair value analysis · CVS fair value analysis